John Lee is a Nephrology physician. ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1542 Medical Park Cir
Tupelo, MS 388016560
Telephone
662-844-4711Registry record last updated 30 Jun 2008.
Clinical trials
- Impact of Nasoseptal Flap Harvest Technique on Olfaction Following Endoscopic Transsphenoidal Pituitary Surgery
Sponsor: Unity Health Toronto
- Indocyanine Green for Central Nervous System Tumors
Sponsor: Abramson Cancer Center at Penn Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
30 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Fresenius USA Marketing, Inc.Program year202515 payments
- Otsuka America Pharmaceutical, Inc.Program year20257 payments
- AstraZeneca Pharmaceuticals LPProgram year20257 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
65%Angiotensin receptor blocker (ARB)18.6%Losartan Potassium76%Olmesartan Medoxomil12%Irbesartan6%Losartan-Hydrochlorothiazide6%Part D<11 patientsLoop diuretic13.6%Torsemide82%Furosemide18%Part D≥69 patients+ 10 more classes in this area
Metabolism & gastrointestinal
18.9%SGLT2 inhibitor14.9%Farxiga60%Jardiance40%Part D≥37 patientsCorticosteroid1.3%Prednisone100%Part D<11 patients+ 3 more classes in this area
Other
7.1%Phosphate Binder4.3%Sevelamer Carbonate100%Part D≥22 patientsDrugs for treatment of hyperkalemia and hyperphosphatemia2.8%Auryxia35%Velphoro33%Lanthanum Carbonate33%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”